Cancer Immune Therapy Edited by G. Stuhler and P. Walden ...

372 17 Immunotoxins and Recombinant Immunotoxins in Cancer Therapy
strom resolution. Proc Natl Acad Sci
USA 83: 1320±4.
56 Hwang J, FitzGerald DJ, Adhya S,
Pastan I (1987) Functional domains of
Pseudomonas exotoxin identified by deletion
analysis of the gene expressed in
E. coli. Cell 48: 129±36.
57 Kounnas MZ, Morris RE, Thompson
MR, FitzGerald DJ, Strickland
DK, Saelinger CB (1992) The a 2macroglobulin
receptor/low density lipoprotein
receptor-related protein binds
and internalizes Pseudomonas exotoxin
A. J Biol Chem 267: 12420±3.
58 Siegall CB, Chaudhary VK, Fitz-
Gerald DJ, Pastan I (1989) Functional
analysis of domains II, Ib, and III of
Pseudomonas exotoxin. J Biol Chem 264:
14256±61.
59 Jinno Y, Ogata M, Chaudhary VK,
Willingham MC, Adhya S, FitzGerald
D, Pastan I (1989) Domain II mutants
of Pseudomonas exotoxin deficient
in translocation. J Biol Chem 264:
15953±9.
60 Idziorek T, FitzGerald D, Pastan I
(1990) Low pH-induced changes in
Pseudomonas exotoxin and its domains:
increased binding of Triton X-114. Infect
Immun 58: 1415±20.
61 Jiang JX, London E (1990) Involvement
of denaturation-like changes in
Pseudomonas exotoxin a hydrophobicity
and membrane penetration determined
by characterization of pH and thermal
transitions. Roles of two distinct conformationally
altered states. J Biol Chem
265: 8636±41.
62 Ogata M, Pastan I, FitzGerald D
(1991) Analysis of Pseudomonas exotoxin
activation and conformational
changes by using monoclonal antibodies
as probes. Infect Immun 59: 407±
14.
63 Carroll SF, Collier RJ (1988) Amino
acid sequence homology between the
enzymic domains of diphtheria toxin
and Pseudomonas aeruginosa exotoxin A.
Mol Microbiol 2: 293±6.
64 Brandhuber BJ, Allured VS, Falbel
TG, McKay DB (1988) Mapping the
enzymatic active site of Pseudomonas
aeruginosa exotoxin A. Proteins 1988; 3:
146±54.
65 Carroll SF, Collier RJ (1987) Active
site of Pseudomonas aeruginosa exotoxin
A. Glutamic acid 553 is photolabeled by
NAD and shows functional homology
with glutamic acid 148 of diphtheria
toxin. J Biol Chem 262: 8707±11.
66 Wozniak DJ, Hsu LY, Galloway DR
(1988) His-426 of the Pseudomonas aeruginosa
exotoxin A is required for ADPribosylation
of elongation factor II. Proc
Natl Acad Sci USA 85: 8880±4.
67 Jinno Y, Chaudhary VK, Kondo T,
Adhya S, FitzGerald DJ, Pastan I
(1988) Mutational analysis of domain I
of Pseudomonas exotoxin. Mutations in
domain I of Pseudomonas exotoxin
which reduce cell binding and animal
toxicity. J Biol Chem 263: 13203±7.
68 Kondo T, FitzGerald D, Chaudhary
VK, Adhya S, Pastan I (1988) Activity
of immunotoxins constructed
with modified Pseudomonas exotoxin A
lacking the cell recognition domain.
J Biol Chem 263: 9470±5.
69 Batra JK, Jinno Y, Chaudhary VK,
et al. (1989) Antitumor activity in mice
of an immunotoxin made with antitransferrin
receptor and a recombinant
form of Pseudomonas exotoxin. Proc
Natl Acad Sci USA 86: 8545±9.
70 Chaudhary VK, Jinno Y, Fitz-
Gerald D, Pastan I (1990) Pseudomonas
exotoxin contains a specific sequence
at the carboxyl terminus that is
required for cytotoxicity. Proc Natl Acad
Sci USA 87: 308±12.
71 Seetharam S, Chaudhary VK, Fitz-
Gerald D, Pastan I (1991) Increased
cytotoxic activity of Pseudomonas exotoxin
and two chimeric toxins ending in
KDEL. J Biol Chem 266: 17376±81.
72 Raag R,Whitlow M (1995) Singlechain
Fvs. FASEBJ 9: 73±80.
73 Winter G, Milstein C (1991) Manmade
antibodies. Nature 349: 293±9.
74 Reiter Y, Brinkmann U, Lee B, Pastan
I (1996) Engineering antibody Fv
fragments for cancer detection and
therapy: disulfide-stabilized Fv fragments.
Nat Biotechnol 14: 1239±45.
75 Choe M,Webber KO, Pastan I (1994)
B3(Fab)±PE38M: a recombinant immunotoxin
in which a mutant form of
Pseudomonas exotoxin is fused to the